We were surprised to see some of Falini's comments and disagreements on our letter, 1 as we actually think that our results and interpretations are quite in accordance with their proposed hypothesis. As it is clearly stated in our report, 2 we have never claimed that 'despite of the bulk mutated NPM1 protein is aberrantly localized in the cytoplasm, some of it is localized in the nucleoli'; as we have analysed a sample from a heterozygous patient for the NPM1 mutation, we interpreted that the observed nucleolar staining pattern in the sample could be owing to the presence of the wild-type protein. If the wild-type protein can be sequestered or not in the cytoplasm by the newly described mutant is something that needs further investigation.
Regarding our immunofluorescence results with a commercially available antibody against NPM1 with samples heterozygous for the already described type-A mutation, we agree that some differences may exist with other studies. We have reassayed additional samples containing type-A mutations in heterozygosis, and found nucleolar and cytoplasmic reactivity (Supplementary Figure 1) . Again, when compared with the new insertional mutation described in our letter, cytoplasmic reactivity is clearly stronger in type-A mutants than in the C-terminal truncated NPM1 mutation. These results reinforce our idea that in some cases, depending on the type of antibody used, and even depending on the processing of samples, this truncating mutation might not be properly detected. Thus we would recommend, for clinical routine analysis, searching for NPM1 mutations by molecular biology methods from DNA/ RNA obtained from patient samples.
In our 'Letter to the editor', 2 we obviously did not pretend to give a mechanistic explanation for the aberrant expression of NPM1 mutant, but highlighted the presence of a new NPM1 mutation in a different gene location, whose prognostic value is still unknown. As we have already mentioned in our report, the fact that Albiero et al. 3 have found the same kind of nucleotide insertion generating a similar truncated protein reinforces the possibility that a new hot spot for mutations in NPM1 has been located.
Much work still needs to be done to understand the role of nucleolar and cytoplasmic variants of NPM1, in both normal and pathological conditions. We acknowledge very much the interesting in vitro studies performed by Falini et al., analysing the cellular localization of NPM1 mutant proteins, hoping that they can give some light to their putative role in leukemogenesis. 
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